Etelcalcetide
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
amifostine
Cytoprotectant (Organic thiophosphate) · Chemoprotectant
Cytoprotectant (Organic thiophosphate)Chemoprotectant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 2 →
- EtelcalcetideSevereDatabaseDDInter
Mechanism
Amifostine is an organic thiophosphate that, upon activation by alkaline phosphatase, acts as a cytoprotective agent against cancer chemotherapy and radiotherapy-induced damage.
Indications
Prophylaxis of cisplatin-induced neurotoxicityProphylaxis of cisplatin-induced nephrotoxicityRadiotherapy-related xerostomia
Side effects
Common
NauseaVomitingHypotensionInfusion-related reaction
Serious
- Hypocalcaemia
Drug interactions
Losartan
Moderate
Database
Increased risk of hypotension
Monitor blood pressure closely. Consider holding losartan for 24 hours before amifostine administration if possible, or reduce amifostine dose.
Source: DDInter
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Infective endocarditis prevention
NICE · Cardiology / Dentistry · 2008
Infective endocarditis prevention
AHA · Cardiology / Dentistry · 2007
Diabetic foot — clinical management
MOHFW · Endocrinology · 2021
Ask House about amifostine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team